Jason Hoffman, PharmD, RPh

Jason Hoffman, PharmD, RPhis a medical writer specializing in the field of oncology and is based in Boston. Jason contributes news articles, creates drug showcases, develops case studies, and maintains the treatment regimen charts on Cancer Therapy Advisor. After studying pharmacy at Northeastern University and working as a pharmacy intern at Dana-Farber Cancer Institute, Jason transitioned to medical communications to have a greater impact on a wider audience. His interests include hiking, playing tennis, and traveling.

Most Recent Articles by Jason Hoffman, PharmD, RPh

Myeloma: Proteasome Inhibitors and IMiDs May Increase Risk of Cardiovascular Complications

Myeloma: Proteasome Inhibitors and IMiDs May Increase Risk of Cardiovascular Complications

By

Patients with underlying cardiovascular disease and/or baseline hypertension and coronary artery disease may be at a higher risk.

NSCLC: Liquid Biopsy May Predict Patient Response to Immune Checkpoint Inhibition

NSCLC: Liquid Biopsy May Predict Patient Response to Immune Checkpoint Inhibition

By

Liquid biopsy can be useful in cases where small bronchial biopsies contain a low number of tumor cells, and the repeatability of liquid biopsies can offer new approaches for monitoring patients treated with immunotherapy.

Cervical Cancer: SLN Biopsy Associated With Fewer Complications

Cervical Cancer: SLN Biopsy Associated With Fewer Complications

By

Sentinel lymph node biopsy was associated with fewer surgical complications, less lymphedema, and better quality of life.

BRCA1, RAD51C Methylation Linked to Response to PARP Inhibitors

BRCA1, RAD51C Methylation Linked to Response to PARP Inhibitors

By

BRCA1 and RAD51C methylation in ovarian carcinomas are associated with sensitivity to PARP inhibitors, such as rucaparib.

Isolated Tumor Cells and Routine Adjuvant Chemotherapy in Endometrial Cancer

Isolated Tumor Cells and Routine Adjuvant Chemotherapy in Endometrial Cancer

By

Patients with endometrial cancer who have isolated tumor cells identified by sentinel lymph node mapping should not routinely receive adjuvant chemotherapy.

More Articles by Jason Hoffman, PharmD, RPh

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters